Aller au contenu principal
2026 article

Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort

0Citations signalées, ce qui n’est pas une note de qualité
70Institutions déclarées
9Pays d’affiliation déclarés

Rattachement africain : cn, us, jp, tw, sg, kr, ro, hk, es. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND & AIMS: Direct-acting antiviral agents (DAA)-mediated HCV cure correlates with better outcomes, but there are insufficient data on detailed mortality-related risk factors after cure. This study sought to clarify mortality and associated risk factors post-HCV cure. METHODS: The study included HCV patients with sustained virological response following DAA (DAA-SVR) from 39 REAL-C centres in North America, Europe and Asia-Pacific. The primary outcome was all-cause mortality in DAA-SVR patients. Mortality rate per 1000 patient-years (PY) was calculated as the number of deaths divided by total PY multiplied by 1000. RESULTS: A total of 10 034 DAA-SVR patients (stratified by cirrhosis status: 5611 non-cirrhosis, 4153 compensated, 270 decompensated) were included. With a median follow-up of 4.76 PY, 4.9% (491) died. The all-cause mortality rates were 6.2, 13.1, 60.0 and 10.4 per 1000 PY for patients without cirrhosis, compensated and decompensated cirrhosis, and overall patients, respectively. The 5-year cumulative survival was 95.1% (94.5%-95.6%) overall, with the lowest rate of 73.9% (67.0%-79.5%) in decompensated cirrhosis. Non-liver-related death was the main cause in non-cirrhosis (non-liver-related vs. liver: 5.2 vs. 0.8 per 1000 PY)/compensated cirrhosis (8.2 vs. 4.8 per 1000 PY), while liver-related death was dominant in decompensated cirrhosis (24.7 vs. 33.8 per 1000 PY). Risk factors for higher mortality included age > 65 (3.2-fold), male (1.5-fold), cirrhosis (decompensated 7.6-fold) and baseline DM (1.5-fold). CONCLUSION: This study showed significant age, sex, fibrosis stage and DM differences in mortality and causes among DAA-SVR patients. It provided granular subgroup data for precision medicine to support individualised care, future modelling studies and public health planning.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort
Date Crossref
22/02/2026
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Second Affiliated Hospital of Xi'an Jiaotong UniversityStanford MedicineStanford UniversityOgaki Municipal HospitalOsaka Metropolitan UniversityTokyo Metropolitan UniversityKyushu University HospitalNagoya City UniversityKaohsiung Medical UniversityKaohsiung Medical University Chung-Ho Memorial HospitalChangi General HospitalSingHealth Duke-NUS Academic Medical CentreYokohama City University Medical CenterYokohama City UniversityKitasato UniversityNippon Medical SchoolE-Da HospitalHanyang UniversityNagoya UniversityKaiser Permanente San Jose Medical CenterSt. Marianna University School of MedicineShinmatsudo Central General HospitalInstitutul Clinic FundeniGood Moonhwa HospitalSaiseikai Niigata Daini HospitalYamagata UniversityTianjin Third Central HospitalTianjin Medical UniversitySaga UniversityUniversity of WashingtonTianjin People's HospitalKagawa Prefectural Central HospitalNanjing Drum Tower HospitalChinese University of Hong KongUniversity of Hong KongNational University of SingaporeNational University HospitalOsaka Medical and Pharmaceutical UniversityDigestive Health Associates of TexasNational Kyushu Medical CenterHaradoi HospitalKawamura HospitalKyushu Central Hospital of the Mutual Aid Association of Public School TeachersFukuoka HospitalKitakyushu Municipal Medical CenterFukuoka City HospitalNippon Steel Yawata Memorial HospitalNational Hospital OrganizationHamanomachi HospitalEulji UniversityEulji University Nowon Eulji Medical CenterSacred Heart HospitalHallym University Sacred Heart HospitalKyung Hee UniversitySoonchunhyang University Hospital SeoulKangbuk Samsung HospitalShanghai University of Traditional Chinese MedicineShuguang HospitalChiba Hokusou HospitalInstituto de Salud Carlos IIIVall d'Hebron Institut de RecercaCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y DigestivasNanoMedical Systems (United States)VA Palo Alto Health Care SystemVall d'Hebron Hospital UniversitariState Key Laboratory of Synthetic ChemistryOno ClinicKyushu UniversityNational Sun Yat-sen UniversityKumamoto University

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Hepatitis C virus researchLiver Disease Diagnosis and TreatmentHIV-related health complications and treatments

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.